10 Jul 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Leading vaccine provider from Taiwan, Adimmune Corp has passed the third phase of clinical trials for H7N9 Avian Influenza vaccine. This, the company said signifies that the vaccine will hit the market anytime soon.
Adimmune, Asia's only EU-GMP-certified pharmaceutical company, said while addressing the media that the vaccine is being developed from a WHO-approved virus strain. "After Adimmune Corporation receives the vaccine strain, the company will still conduct exams on it to confirm the safety and effectiveness of producing the vaccine," Adimmune chairman Mr Steve Chan had said in April.
Mr Lin Tzou-yien, deputy director of the DOH, said that using an H7N9 influenza vaccine strain provided by either the World Health Organisation (WHO) or the US Centers for Disease Control and Prevention will shorten the time required to get the vaccine to the market.
As per the WHO statistics, 131 laboratory-confirmed cases, including 36 deaths have been reported from China.